Meeting
2019 Gastrointestinal Cancers Symposium
Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509).
Authors
Jaume Capdevila
Medical Oncology Department, Vall d’Hebron University Hospital; Vall d’Hebron Institute of Oncology (VHIO)., Barcelona, Spain
Jaume Capdevila , Nicola Fazio , Carlos López-López , Alexandre Teule , Juan W. Valle , Salvatore Tafuto , Ana B. Custodio , Nicholas Reed , Markus Raderer , Enrique Grande , Rocio Garcia-Carbonero , Paula Jiménez-Fonseca , Vicente Alonso , Lorenzo Antonuzzo , Andrea Spallanzani , Alfredo Berruti , Isabel Sevilla , Adelaida La Casta Munoa , Jorge Hernando , Toni Ibrahim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02678780
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 332)
DOI
10.1200/JCO.2019.37.4_suppl.332
Abstract #
332
Poster Bd #
H10
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).
First Author: Jaume Capdevila
Poster
2021 ASCO Annual Meeting
Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).
First Author: Jaume Capdevila
Poster
2015 Gastrointestinal Cancers Symposium
A phase I multicenter study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors (PNET).
First Author: Aparna Kalyan
Poster
2022 ASCO Annual Meeting
ALTER-UC-001: Phase II trial of anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma.
First Author: Hailiang Zhang